Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

OCUL - Ocular Therapeutix, Inc. Последние новости | Finranks

Home

/

OCUL

O

Ocular Therapeutix, Inc. (OCUL)

NGM – Цена в реальном времени. Валюта: USD

10.25

+0.49 (5.02%)

Рынок открыт: Aug 12, 2026, 1:51 PM EDT

9.80

+0.04 (0.41%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees.

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked regulatory path and strong Phase 3 efficacy data. AXPAXLI's annual dosing and clinic productivity benefits could drive adoption beyond wet AMD, targeting broader retinal indications including diabetic retinopathy. The FDA has agreed to an NDA submission in Q4 2026 based on SOL-1 data and interim safety from SOL-R, reducing near-term regulatory risk.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026

Видео

No Data

There is no data to display

Пресс-релизы

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees.

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

03.08.2026

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026